Loading…
Loading…
NIU does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for NIU and 80,000+ other tickers.
See exactly how NIU's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NIU and 80,000+ other tickers.
Niu Technologies, a Chinese company established in 2014 and headquartered in Beijing, specializes in the design, production, and sale of intelligent electric vehicles, primarily focusing on the People's Republic of China market. Its diverse product portfolio covers a broad spectrum of electric mobility, including popular series like the NQi, MQi, UQi, and Gova electric scooters and motorcycles. The company also manufactures KQi electric kick-scooters, NIU Aero and BQi e-bikes, high-performance RQi and TQi electric motorcycles, and YQi hybrid motorcycles. Beyond vehicles, Niu also offers a…
BASEL, Switzerland and LONDON and NEW YORK and DURHAM, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq:ROIV) and Priovant Therapeutics today announced positive results from the Phase 3 CLARITY program evaluating brepocitinib in non-infectious uveitis (NIU). Brepocitinib met the primary endpoint for both the CLARITY-1 and CLARITY-2 studies. Brepocitinib also achieved statistically significant and clinically meaningful benefit on all key secondary endpoints, including measurements of sustained steroid-free quiescence at Week 48, chorioretinal vascular leakage, resolution of macular edema and patient-reported visual functioning. These results were achieved despite a substantially more aggressive steroid taper than precedent NIU trials.
BEIJING, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Niu Technologies (“NIU” or “the Company”) (NASDAQ: NIU), the world's leading provider of smart urban mobility solutions, today announced that it will report its financial results for the third quarter 2026 before the U.S. market opens on Monday, November 16, 2026.
BEIJING, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Niu Technologies (“NIU” or “the Company”) (NASDAQ: NIU), the world's leading provider of smart urban mobility solutions, today provided its sales volume results for the third quarter of 2026.
The Q2 FY2026 report was a disappointment overall because while it puts NIU on track to end FY2026 with new records, earnings also got worse. The decrease in earnings are the result of several factors and there is reason to think this decrease is not something permanent. There is a silver lining to be found because NIU is still in position to improve over time, which combines well with its relatively low valuations.
Niu Technologies (NIU) Q2 2026 Earnings Call Prepared Remarks Transcript